Male Reproductive System

Male Reproductive Health Study Notes

Overview

  • Topics Covered:
    • Testicular Cancer
    • Benign Prostatic Hyperplasia
    • Prostate Cancer
    • Erectile Dysfunction

Testicular Cancer

Incidence and Significance
  • 1% of all male cancers
  • Major cancer diagnosis in men aged 15-35
  • Highly curable with appropriate treatment
Risk Factors
  • Cryptorchidism: Undescended testicles, increasing cancer risk
  • Family history: Genetic predisposition
  • Ethnicity: Higher prevalence in Caucasians
  • HIV infection: Increased susceptibility to developing testicular cancer
Types of Tumors (Germ Cell Tumors - 95% of cases)
  1. Seminomas
    • Arise from immature germ cells
    • Characteristics: Slow-growing, non-aggressive, highly responsive to radiation
  2. Nonseminomas
    • Arise from mature germ cells
    • Characteristics: More aggressive, typically require surgical intervention
Early Clinical Manifestations
  • Enlargement of the testicle
  • Painless mass detected in the testicle
  • If discomfort occurs (30-40% of cases):
    • Dull ache in the groin
    • Sensation of heaviness
Late Clinical Manifestations
  • Possible acute pain
  • Symptoms indicating metastatic spread:
    • Cough and hemoptysis (coughing blood)
    • Swelling in lower extremities
    • Back pain
    • Dizziness

Benign Prostatic Hyperplasia (BPH)

The Prostate
  • Surrounds the urethra, producing seminal fluids
  • Normal weight ranges between 4-20 grams
Definition and Risk Factors
  • BPH: Nonmalignant enlargement of the prostate
    • Increased average of epithelial cells: 11.9%
    • Increased smooth muscle cells: 38.8%
    • Increased stromal cells: 38.6%
  • Lower urinary tract symptoms (LUTS) are common in BPH
Risk Factors
  • Non-modifiable: Age, family history, race/ethnicity
  • Modifiable: Obesity, metabolic syndrome, caffeine intake, physical activity levels
Etiology: Two Theories
  1. Hormone Imbalance: Involvement of testosterone and estrogen (estradiol)
  2. DHT Accumulation:
    • DHT: Dihydrotestosterone
    • Formed via the reaction: extTestosterone+5extalpha−reductase<br/>ightarrowextDHText{Testosterone} + 5 ext{ alpha-reductase} <br /> ightarrow ext{DHT}
    • Importance:
      • Influences skin (acne production)
      • Affects hair follicles (facial and body hair) but leads to hair loss on the scalp
      • Stimulates prostate cell growth
Clinical Manifestations
  • Symptoms include:
    • Frequency and urgency of urination
    • Delay in initiation of urine flow
    • Reduction in force of urine stream
    • Increased time to urinate
    • Dribbling at the end of urination
Complications
  • Possible obstruction leading to:
    • Urinary tract infections (UTIs)
    • Renal problems due to urinary blockage
Treatment of BPH
  • Mild symptoms: Watchful waiting approach
  • Moderate symptoms: Drug therapy
    • 5-alpha-reductase inhibitors
    • Alpha1-adrenergic antagonists
  • Severe symptoms: Consider invasive surgical options
Medications
  1. 5-alpha-reductase Inhibitors
    • Example: Finasteride (Proscar)
    • Indication: Mechanical obstruction of the urethra
    • Mechanism of Action (MOA): Blocks the conversion of testosterone to DHT
      • Decreases volume of epithelial tissue in the prostate
    • Note: Effectiveness may vary based on prostate size
    • Adverse Effects:
      • Impotence (5-10%)
      • Decreased libido
      • Gynecomastia (abnormal breast tissue enlargement)
    • Caution: Handling should be cautious due to potential side effects
  2. Dutasteride (Avodart)
    • Similar indications and MOA to finasteride, but acts on both alpha 1 & 2 receptors
  3. Alpha1-Adrenergic Antagonists
    • Prototype: Tamsulosin (Flomax)
    • MOA: Relaxes smooth muscle in the prostate
    • Indication: Dynamic obstruction of the urethra
    • Adverse Effects: Generally well tolerated, but may cause abnormal ejaculation
  4. Combination Therapy
    • Example: Dutasteride + Tamsulosin (Jalyn)
    • FDA approved for BPH management; evidence suggests combining these produces better outcomes than monotherapy

Prostate Cancer

Overview
  • Most common male cancer diagnosed in the U.S.
  • Second leading cause of cancer-related deaths, following lung cancer
Demographics
  • Higher incidence in African-American men
  • Lower incidence in Asian and Native American men
  • Rapid increase in risk after age 50
  • Over 80% of cases occur in men aged 65 or older
Risk Factors
  • Age: Increased risk with age
  • Ethnicity: Variations observed across different races
  • Family history: Genetic predispositions play a significant role
  • Diet: High-fat diet associated with increased risk
Clinical Manifestations
  • Early symptoms resemble BPH-type presentations
  • Late manifestation might include:
    • Symptoms associated with metastasis (e.g., bone pain, lung issues)
Prognosis
  • Dependent on stage of cancer at diagnosis
  • Early diagnosis improves outcomes significantly
Controversy Surrounding Prostate Cancer
  • Many prostate cancer cases are indolent and may never become clinically significant
  • Historical emphasis on PSA screening prior to sufficient evidence supporting its efficacy
Benefits and Harms of PSA Screening
  • Benefits: Possible small survival benefit noted; dramatic drop in prostate cancer deaths since PSA testing commenced
  • Harms:
    • Frequent occurrence of unnecessary biopsies
    • Treatment side effects include erectile dysfunction, urinary incontinence, and bowel problems
Prognostic Factors for Prostate Cancer

-Grade of cancer based on the Gleason score—higher scores indicate worse prognosis

  • Tumor volume and PSA levels—higher/rapidly rising PSA levels correlate with worse outcomes
  • Comparison of detection methods: PSA test versus digital rectal exam (DRE)

Erectile Dysfunction (ED)

Definition and Significance
  • Also known as IMPOTENCE
  • Defined as the inability to achieve or sustain an erection sufficient for satisfactory sexual intercourse
  • Approximately 30 million men in the U.S. affected, often associated with chronic illness
Classification of ED
  1. Primary ED (rare): Lifelong inability to maintain an erection, often due to severe psychiatric problems or early vascular trauma
  2. Secondary ED (most common): History of normal erections followed by erectile failure
Etiology of Secondary ED
  • Organic Causes:
    • Peripheral vascular disease and arterial insufficiency
    • Sedentary lifestyle as a risk factor
    • Endocrine disorders affecting hormone levels
  • Psychogenic Causes:
    • Depression, performance anxiety, trauma, etc.
Physiology of a Normal Erection
  • Begins with sexual arousal leading to:
    • Increased parasympathetic nervous system (PNS) activity and nitric oxide release
    • Activation of cyclic guanosine monophosphate (cGMP)
    • Vascular smooth muscle relaxation, allowing blood inflow and erection
    • PDE-5 (phosphodiesterase type 5) enzyme role in breaking down cGMP, thus regulating erection
PDE-5 Inhibitors
  • Prototype: Sildenafil (Viagra)
  • MOA: Inhibits PDE5, preserving cGMP levels, enhancing erections in response to sexual stimuli
  • Indications: Treatment of ED, pulmonary arterial hypertension, and management of BPH
Sildenafil (Viagra) Usage Information
  • Timing: Effective up to 4 hours prior to sexual activity, onset within 30-60 minutes
  • Adverse Effects: Common effects include headaches (16%), flushing (10%), and dyspepsia (7%)
  • Precautions: Avoid use in conjunction with nitrates; risk of hypotension
  • Safety Issues to Discuss:
    • Ask patients to contact emergency services if they experience severe pain or signs of heart attack during sexual activity
    • Awareness of potential sudden loss of vision or hearing
    • Limit usage to once per day
    • Priapism: Prolonged erection exceeding 4 hours is a medical emergency requiring immediate treatment

References

  • Acknowledgements: Lynn Kelso DNP, APRN, FCCM, FAANP
  • Sources include:
    • Capriotti, T. M., & Frizzell, J. P. "Pathophysiology: Introductory Concepts and Clinical Perspectives." FA Davis Company.
    • Nickel JC. "Comparison of Clinical Trials with Finasteride and Dutasteride." Rev Urol. 2004.
    • Dimitropoulos, K., & Gravas, S. "Fixed-Dose Combination Therapy with Dutasteride and Tamsulosin in the Management of Benign Prostatic Hyperplasia." Therapeutic Advances in Urology, 2016.
    • Articles and guidelines from UpToDate related to prostate cancer and testicular germ cell tumors.